In contrast, CALCA and PRDM16 polymorphisms showed moderate evidence, and GRIA1 and SCN1A showed weaker evidence to explain nonresponsive migraine patients to Triptan treatment. This evidence concerns the gene GRIA1 and migraine disorder.